Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Intel is scheduled to report second-quarter results after the closing bell Thursday, with analysts tracked by Visible Alpha unanimously neutral amid questions surrounding the company's foundry ...